If you have been reading about copper tripeptide and want a single page that covers the useful parts, this is it: definitions, context, how it is studied, and the questions that come up repeatedly.
Updated 2025-11-30. Numbers and descriptions here follow the published literature rather than marketing material.
GHK-Cu is a coordination complex formed between the tripeptide glycyl-L-histidyl-L-lysine and a copper(II) ion. The peptide backbone consists of glycine, histidine, and lysine joined in that order. Copper is held through the imidazole nitrogen of histidine and the alpha-amino group at the N-terminus, which together produce a square-planar arrangement around the metal center. The solid appears blue to violet, a color that originates from d-d electronic transitions within the copper coordination sphere. The complex is indexed under CAS number 89030-95-5.
The sequence now called GHK was first reported in the early 1970s after isolation from human plasma, where it was noted to influence liver cell behavior in laboratory preparations. Later work described a copper-binding form and its activity in fibroblast and wound-model experiments. Review articles frequently group the substance with other copper peptides. Concentrations in blood appear to fall with age in several small surveys, although the reason for this trend is not settled. Whether such a decline carries functional consequences remains an open question.
Published work on GHK-Cu concentrates largely on cell culture systems rather than whole organisms. Frequently used endpoints include collagen synthesis, expression of matrix metalloproteinases, and migration of fibroblasts. Some reports describe antioxidant behavior, while others stress delivery of copper into cells. These mechanisms are proposed rather than demonstrated, and the relative weight of each pathway is unclear. Human trials are few and generally small, so laboratory findings should not be read as confirmed clinical results.
Solid material is typically kept as a lyophilised powder in a sealed, light-protected container at minus 20 degrees Celsius, with desiccant where humidity is high. Working solutions are often prepared fresh, aliquoted and frozen to avoid repeated freeze-thaw cycles. Glassware and buffers are checked for trace metal contamination, since other transition metals can displace copper. Records of lot number, reconstitution date and storage temperature help trace unexpected colour changes. Blue colour itself is not a reliable purity test, because partly degraded solutions can remain visibly coloured.
Identity and purity are normally checked by reversed-phase high-performance liquid chromatography, often coupled to mass spectrometry. The peptide absorbs in the ultraviolet region, and the copper complex also shows a broad visible absorption band that can be followed spectroscopically. Copper content is measured separately, for example by inductively coupled plasma mass spectrometry or atomic absorption spectroscopy, because the peptide assay alone does not confirm how much metal is bound. Purity figures therefore need a stated basis: peptide peak area, copper content, or both.
Aqueous GHK-Cu solutions are less stable than the dry powder. Light, dissolved oxygen and elevated temperature all accelerate loss of the intact complex, and the main observable changes are fading of the blue colour and the appearance of peptide fragments. Acidic conditions protonate the histidine imidazole and weaken copper binding, while strongly alkaline conditions promote hydrolysis of the peptide backbone. Because several degradation routes operate at once, a single shelf-life figure does not describe all storage conditions.
| Property | Value | Notes |
|---|---|---|
| Chemical class | Copper(II) peptide complex | Peptide chain coordinated to a single metal ion |
| CAS number | 89030-95-5 | Indexed for the peptide-copper complex |
| Molecular formula | C14H22CuN6O4 | Approximate formula for a one-to-one complex |
| Appearance | Blue to violet solid | Color from copper d-d transitions |
| Solubility class | Freely soluble in water | Also dispersible in some polar solvents |
GHK-Cu is the copper-binding complex formed by the tripeptide glycyl-L-histidyl-L-lysine and a copper(II) ion. The free peptide is usually written as GHK, and the complex is written as GHK-Cu or Cu-GHK. The sequence was identified in human plasma and later detected in saliva and urine. Its name comes from the single-letter codes of glycine, histidine and lysine. The complex is widely described as a naturally occurring carrier of copper in blood rather than as a free peptide with its own hormonal role.
Copper binds to the peptide through the histidine imidazole nitrogen and the terminal amino group, forming a stable square-planar complex. Binding constants reported for copper(II) with GHK are high, so the peptide competes effectively for copper in solution. The complex absorbs visible light, which gives solutions a blue to violet colour. Whether the metal-free peptide has a distinct biological function of its own is still an open question; some work treats it mainly as a copper delivery vehicle, while other work reports peptide-specific effects.
The compound was first isolated from human plasma in the 1970s by Loren Pickart, who later described copper-binding activity in liver and other tissues. Early reports focused on its presence in blood and its ability to carry copper between proteins. Commercial and cosmetic use of the term 'copper peptide' has since broadened, and labels rarely distinguish GHK-Cu from other copper-binding fragments. This naming overlap makes literature searching harder, because cosmetic ingredient lists, supplier catalogues and laboratory papers use different vocabularies for the same molecule.
Copper takes part in redox chemistry, and the same property that makes it useful in enzymes can generate reactive oxygen species when the ion is loosely bound. GHK chelates copper through imidazole, amino, and amide nitrogen donors, which reduces the amount of free copper in solution. Whether that chelation is protective, neutral, or harmful in a given tissue is not settled. Laboratory assays report both antioxidant and pro-oxidant behavior, depending on the conditions and the readout used.
Published work on GHK-Cu is dominated by in vitro experiments and small animal studies. Human trials tend to be short and small, with endpoints such as skin appearance rather than clinical outcomes. Review articles often summarize the same underlying laboratory findings, which can make the evidence base look broader than it is. Several basic questions remain open: the concentration of the intact complex in human tissue, the route by which it crosses the skin barrier, and whether effects seen in culture produce measurable changes in people.
Laboratory studies describe GHK-Cu as a source of copper that cells can take up, with reported effects on collagen, elastin, and glycosaminoglycan synthesis in cultured fibroblasts. The peptide also appears in wound-repair research, where it is linked to the activity of matrix metalloproteinases and their inhibitors. These observations come largely from cell and animal models. How directly the complex controls any single pathway in intact human skin remains an open question, and reported effects depend on concentration, vehicle, and exposure time.
Additionally, H-DNA has been shown to cause mutations related to critical cellular processes like DNA replication and transcription. The importance of these processes for survival has led to the development of complex DNA repair mechanisms that allow cells to recognize and fix DNA damage. Non-canonical DNA structures can be perceived as damage by the cell, and recent work has shown an increased prevalence of mutations near non-B-DNA-forming sequences. Some of these mutations are due to the interactions between H-DNA and the enzymes involved in DNA replication and transcription, where H-DNA interferes with these processes and triggers various DNA repair mechanisms. This can cause genetic instability and implicates H-DNA in cancer formation.
{\displaystyle \mathbf {P} ={\begin{bmatrix}\mathrm {R} _{1}\mathrm {R} _{2}\mathrm {R} _{3}\mathrm {R} _{4}\mathrm {R} _{5}\mathrm {R} _{6}\mathrm {R} _{7}\cdots \mathrm {R} _{L}\end{bmatrix}}\qquad {\text{(1)}}}
==== Delivery methods ==== Honokiol is most commonly taken orally. There are a number of supplements available containing honokiol. Magnolia tea made from the bark of the tree is also a common delivery method of honokiol. Both Native American and Japanese medicine use tea gargles to treat toothaches and sore throats. Because honokiol is highly hydrophobic it must be dissolved in a lipid for many delivery methods. In many current animal studies the compound is dissolved in a lipid emollient and delivered through intraperitoneal injection. There is ongoing work developing liposomal emulsions for IV delivery.
Valve was founded in 1996 by the former Microsoft employees Gabe Newell and Mike Harrington. Newell had spent the prior 13 years at Microsoft developing Windows, including the Windows 95 port of Doom from id Software. Newell had become frustrated with game developers' approach of creating bespoke interfaces for graphics acceleration, and had also seen id Software outperforming Windows in sales of Doom with an alternative distribution model. Newell and Harrington founded Valve, L.L.C. in Kirkland, Washington, about five miles from the Microsoft campus in Redmond, on August 24, 1996, Newell's wedding day. In a break from industry style of the time, Newell did not want a company name that suggested "testosterone-gorged muscles and the 'extreme' of anything". Alternative names considered by Newell and Harrington include Hollow Box, Fruitfly Ensemble and Rhino Scar. Valve's first game was Half-Life, a first-person shooter (FPS) with elements of horror. The development was aided by access to the Quake engine by id Software; Valve modified this engine into its GoldSrc engine. After struggling to find a publisher, Valve eventually signed with Sierra On-Line. Half-Life was released in November 1998 and was a critical and commercial success. With its realism, scripted sequences and seamless narrative, it had a lasting influence; according to IGN in 2014, the history of the FPS genre "breaks down pretty cleanly into pre-Half-Life and post-Half-Life eras".
Sources: en.wikipedia.org
==== The Fourth Government (1989–1993) ==== Felipe González called general elections for October 1989, in which he again renewed his absolute majority but this time by only one seat. The People's Party born from the "refoundation" of Alianza Popular carried out in the extraordinary Congress held in January of that same year, ran in the elections. As candidate for the presidency of the government, Manuel Fraga proposed José María Aznar, then president of the Junta of Castile and León. The "re-founded" PP won 25.6% of the votes and 107 seats, and in March 1990, during the 10th Congress, Aznar was elected president of the PP, while Manuel Fraga held the presidency of the Xunta de Galicia after winning the autonomous elections held in December 1989. The first of the scandals that gradually undermined confidence in the PSOE and its government was the "Guerra case", named after the brother of the vice-president of the government who was accused of illicit enrichment and influence peddling. At first Alfonso Guerra refused to resign and the PSOE leadership supported him, but finally Felipe González had no choice but to dismiss him in January 1991. The departure of Alfonso Guerra's government deepened the internal division of the PSOE that had manifested itself in the 32nd Congress held in November 1990 and triggered a dull struggle between guerristas and renovadores that worsened with the outbreak in May 1991 of a new corruption scandal, the "Filesa case", which this time involved the whole party.
== Treatment == Recommendations to treat pressure ulcers include the use of bed rest, pressure redistributing support surfaces, nutritional support, repositioning, wound care (e.g., debridement, wound dressings) and biophysical agents (e.g., electrical stimulation). Reliable scientific evidence to support the use of many of these interventions, though, is lacking. More research is needed to assess how to best support the treatment of pressure ulcers, for example by repositioning.
The COVID-19 pandemic in North Korea was part of a global pandemic of coronavirus disease 2019 (COVID-19), a novel infectious disease caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). North Korea confirmed its first case on 8 May 2022. North Korea is a secretive and diplomatically isolated country in East Asia. Its weak healthcare system and impoverished population led to concerns over the country's vulnerability to an outbreak, though its cold chain vaccination program had proven capable in prior pandemics. With a totalitarian political system, little information on the pandemic's impacts on North Korea has been available to international observers. In January 2020, the North Korean government began taking extensive measures to protect itself from the initial COVID-19 outbreak, including the establishment of quarantine facilities, and strict travel restrictions. In March and April 2020, the Asia Times and 38 North reported that these measures seemed largely successful. Before May 2022, the government of North Korea had not reported any confirmed cases of COVID-19, although some foreign analysts believed that the virus had spread there by March 2020. Daily NK, a South Korean dissident-run news website, said that about 180 soldiers had possibly died from COVID-19 symptoms in January and February 2020. In July 2020, a single suspected case in Kaesong prompted a three-week lockdown. By 2021, there were increasing reports that the isolation imposed to avoid the pandemic was having a major impact on the economy.
Sources: en.wikipedia.org
It is the copper complex of the tripeptide glycyl-L-histidyl-lysine. The metal ion is held by the histidine imidazole group and the peptide N-terminus. Most research on it concerns skin and wound models.
The tripeptide was first isolated from human plasma and has also been reported in saliva and urine. Plasma levels appear to decline with age in some small studies. Those observations rest on limited sample sizes.
It is not authorized as a systemic medicine in most countries. Cosmetic preparations list it as an ingredient rather than an active pharmaceutical substance. Legal status therefore differs by jurisdiction.
The colour depends on copper held in a specific coordination environment. When the complex dissociates or the peptide is cleaved, that environment changes and the visible absorption weakens.